Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Chunduri, S.; Dobogai, L. C.; Peace, D.; Saunthararajah, Y.; Quigley, J.; Chen, Y.-H.; Mahmud, N.; Hurter, E.; Beri, R.; Rondelli, D.
June 2008
Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p935
Academic Journal
In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18�61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an allogeneic hematopoietic SCT (HSCT) from HLA-matched related (n=16) or unrelated (n=20) donors. The source of hematopoietic stem cells was peripheral blood in 28 and marrow in 8 cases. Rabbit-antithymocyte globulin at 7 mg/kg was utilized in 21 patients. Acute GVHD grade II�IV was observed in 19% of the patients (grade III�IV in 14% of patients) and chronic GVHD in 11 of 30 evaluable patients (37%). At median follow-up of 737 days (range: 152�1737) for alive patients, overall survival rates in standard- and high-risk patients were 80 and 35%, respectively, and event-free survival rates were 70 and 31%, respectively. TRM was 10% in standard-risk and 19% in high-risk patients. Post transplant relapse was observed in 20% standard-risk and in 46% high-risk patients. FluBU conditioning regimen is associated with a limited hematologic and extrahematologic toxicity and with an antitumor activity comparable to other standard myeloablative regimens.Bone Marrow Transplantation (2008) 41, 935�940; doi:10.1038/bmt.2008.13; published online 11 February 2008


Related Articles

  • The hematopoietic stem cell transplantation in Indonesia: an unsolved dilemma. Hariman, H. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS85 

    Allogeneic BMT was performed in Indonesia, but had to be stopped prematurely because of the small number of patients. In the beginning, only patients with sufficient financial resources to travel to western countries could undergo transplant procedures. When neighbouring countries (Singapore and...

  • Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Beri, R.; Chunduri, S.; Sweiss, K.; Peace, D. J.; Mactal-Haaf, C.; Dobogai, L. C.; Shord, S.; Quigley, J. G.; Chen, Y. H.; Mahmud, N.; Rondelli, D. // Bone Marrow Transplantation;Feb2010, Vol. 45 Issue 2, p249 

    A pretransplant test dose of i.v. BU was previously used in pediatric patients undergoing a reduced-intensity allogeneic hematopoietic SCT (HSCT). Here, we used a BU test dose in 23 adult patients who were not pancytopenic and underwent a myeloablative allogeneic HSCT prepared with fludarabine...

  • Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells. Goldstein, Gal; Toren, Amos; Nagler, Arnon // Current Pharmaceutical Design;May2007, Vol. 13 Issue 13, p1363 

    Human umbilical cord blood (CB) has established itself as a legitimate source for hematopoeitic stem cell transplantations. Since the first transplantation was preformed in 1988, it is estimated that approximately 4,000 patients, with malignant and non-malignant diseases, were transplanted with...

  • Subsets of CD34+ and early engraftment kinetics in allogeneic peripheral SCT for AML. Pastore, D.; Mestice, A.; Perrone, T.; Gaudio, F.; Delia, M.; Albano, F.; Russo Rossi, A.; Carluiccio, P.; Leo, M.; Liso, V.; Specchia, G. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p977 

    This study aimed to identify which graft product subset of CD34+ cells might be the most predictive of early hematopoietic recovery following allogeneic peripheral SCT (allo-PBSCT). The relationship between the number of �mature� subsets of CD34+ cells (CD34+/CD33+, CD34+/CD38+,...

  • Reduced respiratory and skeletal muscle strength in survivors of sibling or unrelated donor hematopoietic stem cell transplantation. Kovalszki, A.; Schumaker, G. L.; Klein, A.; Terrin, N.; White, A. C. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p965 

    We performed a retrospective analysis of muscle strength testing obtained following sibling or unrelated donor hematopoietic stem cell transplant (HSCT) between 1 January 1999 and 31 December 2003 in a cohort of 44 subjects at Tufts-New England Medical Center. Maximal inspiratory pressure...

  • Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Marks, D. I.; Aversa, F.; Lazarus, H. M. // Bone Marrow Transplantation;Oct2006, Vol. 38 Issue 7, p467 

    Myeloablative sibling-matched allogeneic transplantation for adult acute lymphoblastic leukaemia provides the best outcome, but most patients lack a suitable, related histocompatible donor. We reviewed three haematopoietic stem cell donor sources used for alternative donor transplantation...

  • Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Duncan, C. N.; Buonanno, M. R.; Barry, E. V.; Myers, K.; Peritz, D.; Lehmann, L. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p971 

    Bronchiolitis obliterans (BrOb) is a well-recognized complication of allogeneic hematopoietic stem cell transplantation (HSCT). It is associated with substantial morbidity and mortality in adult patients. However, the incidence and morbidity of this complication have not been well described in...

  • Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bashoura, L.; Gupta, S.; Jain, A.; Couriel, D. R.; Komanduri, K. V.; Eapen, G. A.; Safdar, A.; Broglio, K. R.; Adachi, R.; Dickey, B. F. // Bone Marrow Transplantation;Jan2008, Vol. 41 Issue 1, p63 

    Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other...

  • Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. van Besien, K; Devine, S; Wickrema, A; Jessop, E; Amin, K; Yassine, M; Maynard, V; Stock, W; Peace, D; Ravandi, F; Chen, Y-H; Cheung, T; Vijayakumar, S; Hoffman, R; Sosman, J // Bone Marrow Transplantation;Jul2003, Vol. 32 Issue 1, p9 

    Summary:Fludarabine, thiotepa and total body irradiation (TBI) has been used as conditioning in haplo-identical transplantation. We studied this conditioning regimen in adults undergoing matched sibling transplantation and alternative donor transplantation. A total of 30 consecutive patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics